Problem: Women with antiphospholipid antibodies (aPL) are at risk for pregnancy complications despite treatment with low molecular weight heparin (LMWH) or aspirin (ASA). aPL recognizing beta 2 glycoprotein I can target the uterine endothelium, however, little is known about its response to aPL. This study characterized the effect of aPL on human endometrial endothelial cells (HEECs), and the influence of LMWH and ASA.
Studies regarding each medication's effectiveness for preventing RPL in the setting of aPL are controversial, [8] [9] [10] [11] [12] especially in light of histological studies, which confirm inflammation rather than intraplacental thrombosis at the maternal-fetal interface. 6 Moreover, despite treatment, pregnant patients with APS continue to have high rates of preeclampsia and preterm birth. [13] [14] [15] [16] Experimental studies have further confirmed the lack of thrombosis, and instead demonstrated inflammation and placental insufficiency as the underlying pathogenesis for obstetric APS. [17] [18] [19] [20] Thus, any beneficial effects of LMWH may be through mechanisms distinct of its anticoagulant properties.
18,21-23
The majority of human in vitro studies have focused on how aPL impact the placental trophoblast. Anti-β 2 GPI aPL induce a pro-inflammatory, anti-angiogenic, and antimigratory profile in trophoblast cells, leading to their diminished ability to interact with and replace the endothelial cells found within the uterine spiral arteries. [18] [19] [20] Furthermore, a role for the innate immune Toll-like receptor 4 (TLR4) in initiating aPLinduced trophoblast inflammation has been demonstrated. 22 The serum glycoprotein, β 2 GPI, localizes not only to the placental trophoblast but also to the uterine endothelium. 4 As result, aPL recognizing β 2 GPI can also affect the maternal side of the uteroplacental interface by binding directly to the endometrial endothelial cells [24] [25] [26] ;
the same cells that the trophoblast interacts with and replaces during normal spiral artery transformation. 27 However, much about the action of aPL on these human endometrial endothelial cells (HEECs) is still unclear. Most aPL-endothelial interactions have been studied using fetus-derived human endothelial cells from umbilical veins (HUVECs)
as a model for systemic vascular events in APS. Similar to findings in the trophoblast, 22 aPL recognizing β 2 GPI are able to bind HUVEC TLR4, activate the TLR4/MyD88 signaling pathway, [28] [29] [30] and induce an inflammatory cytokine/chemokine response. 29, 31 The objective of this study was to elucidate the influence that anti-β 2 GPI aPL have on the maternal uterine vasculature using human endometrial endothelial cells (HEECs) and to investigate the role of TLR4. This study also sought to evaluate the current therapeutic strategy of LMWH and ASA in counteracting any influences aPL had on HEEC function.
| MATERIALS & METHODS

| Reagents
Sterile low molecular weight heparin (LMWH) (enoxaparin sodium injection; 100 mg/mL), was purchased from Aventis Pharmaceuticals, 
| Human endothelial cells
The human endometrial endothelial cells (HEECs) used in this study were originally isolated from the microvasculature of cycling endometrium of multiple women, and all stages of cycles were pooled. 37 Cell culture was performed as previously described 32, 35 and both cell types were cultured in Endothelial Basal Medium-2 (EBM-2) supplemented with 2% fetal bovine serum (FBS) (Lonza; Allendale, NJ).
| Antiphospholipid antibodies
This study used the aPL, IIC5, which is a mouse IgG1 anti-human 
| Angiogenesis assay
An endothelial tube formation assay was used to measure angiogenesis as previously described. 
| Statistical analysis
Each experiment was performed at least three times. All analyses were performed at least in duplicate. All data are reported as either mean ± SEM of pooled experiments for bar charts, or median and quartiles ± SD for box plots of pooled experiments. Statistical significance was set at P < .05 and determined using Prism Software (GraphPad, Inc; La Jolla, CA). For normally distributed data, significance was determined using either one-way analysis of variance (ANOVA) for multiple comparisons or a t test. For data not normally distributed, significance was determined using a nonparametric multiple comparison test for multiple comparisons or the Wilcoxon matched-pairs signed rank test.
| RESULTS
| aPL alter HEEC angiogenic factor and chemokine secretion
The first objective of this study was to measure the effects of aPL on the HEEC angiogenic and cytokine/chemokine factor profile. Compared to the no treatment (NT) control, aPL significantly increased HEEC secretion of pro-angiogenic VEGF by 20.5 ± 8.7-fold; pro-angiogenic PlGF by 3.7 ± 0.8-fold; and anti-angiogenic sFlt-1 by , and all other factors tested by multiplex were below the assay's detection limit (data not shown).
| aPL induce a distinct angiogenic factor and chemokine profile in HUVECs
Since HUVECs are commonly used as a model for the study of the endothelium in APS, 
| aPL inhibition of HEEC MCP-1 secretion is mediated by TLR4
Having established the HEEC angiogenic and chemokine profile induced by aPL, the next objective was to investigate the mechanism involved by blocking TLR4 function using the antagonist, LPS-RS. aPL- by HEECs (Figure 3 ).
| aPL inhibit HEEC angiogenesis
The next objective was to determine whether aPL affected vascular Compared to the NT/media control, LMWH alone significantly decreased basal levels of HEEC GRO-α secretion by 9.7 ± 3.1% ( Figure 5 and Table 1 ). Ethanol alone was run as a control for ASA and had no effect on any of the factors tested (data not shown), with the exception of GRO-α, which was significantly inhibited by 25.9 ± 8.1%. Thus, ASA, either alone or in combination with LMWH, was excluded from the GRO-α analysis.
LMWH alone significantly reduced the aPL-induced upregulation of HEEC VEGF secretion by 24.6 ± 13.5%. However, ASA, either alone or in combination, had no effect on VEGF production in the presence of aPL. LMWH in combination with ASA significantly augmented the aPL-induced upregulation of HEEC PlGF by 1.1 ± 0.0-fold. However, LMWH alone or ASA alone had no effect on PlGF production in the presence of aPL. LMWH either alone, or in combination with ASA, significantly augmented the aPL-induced upregulation of HEEC sFlt-1 by 1.4 ± 0.1-fold and 1.6 ± 0.1-fold, respectively, while ASA alone had no effect. LMWH and ASA, either alone or in combination, had no F I G U R E 1 Effect of aPL on HEEC angiogenic factor and chemokine secretion. HEECs were treated with no treatment (NT), aPL, or control IgG. Data are pooled from 9 independent experiments. Box plots show secreted levels of VEGF; PlGF; sFlt-1; sEndoglin; MCP-1; G-CSF; GRO-α; IL-8; and GM-CSF as determined by ELISA and multiplex analysis. *P < .05 relative to the NT control F I G U R E 2 Effect of aPL on HUVEC angiogenic factor and chemokine secretion. HEECs were treated with no treatment (NT), aPL, or control IgG. Data are pooled from 3 independent experiments. Box plots show secreted levels of VEGF; PlGF; sFlt-1; sEndoglin; MCP-1; G-CSF; GRO-α; IL-8; and GM-CSF as determined by ELISA. *P < .05 relative to the NT control F I G U R E 3 Effect of TLR4 inhibition on aPL-induced HEEC angiogenic factor and chemokine secretion. HEECs were treated with no treatment (NT) or aPL in the presence of media or LPS-RS. Supernatants were measured by ELISA for VEGF; PlGF; sFlt-1; MCP-1; G-CSF; and GRO-α. Data are pooled from 3 independent experiments. *P < .05 relative to the matching NT control for each condition (media or LPS-RS) unless otherwise indicated effect on the ability of aPL to reduce HEEC MCP-1 secretion. ASA either alone or in combination with LMWH significantly and further reduced the aPL-mediated inhibition of HEEC G-CSF by 25.6 ± 4.8% and 17.4 ± 8.9%, respectively, while LMWH alone had no effect. LMWH alone further reduced the aPL-mediated inhibition of HEEC GRO-α secretion by 14.4 ± 5.0% ( Figure 5 and Table 1 ).
| Effect of LMWH and ASA on HEEC angiogenesis in the presence and absence of aPL
When compared to the NT/media control, HEEC tube formation was significantly reduced by 27.9 ± 15.1% in the presence of ASA alone, by 30.2 ± 14.2% in the presence of LMWH alone, and by 24.1 ± 14.5%
in the presence of combination LMWH and ASA ( Figure 6 ). The ethanol control had no effect on the basal HEEC tube formation (data not shown). As already determined, treatment of HEECs with aPL significantly inhibited HEEC tube formation by 26.3 ± 9.1% compared to the NT/media control. LMWH and ASA, either alone or in combination, had no additional effect on the numbers of HEEC tubes formed in the presence of aPL ( Figure 6 ).
| DISCUSSION
Obstetric APS, once thought of as a thrombotic disease, is now known to be inflammatory in origin and associated with placental insufficiency and reduced vascular development and remodeling. 6 One major way in which aPL negatively impact pregnancy is by targeting the placenta, altering trophoblast function. [18] [19] [20] During pregnancy, aPL recognizing β 2 GPI can also affect the maternal side of the interface by binding directly to the uterine endothelium, 4,24-26 which provides the scaffolding upon which trophoblast cells transform the maternal spiral arteries. 27 However, little is known about how aPL influence the function of these human endometrial endothelial cells (HEECs). Furthermore, little is known about the impact the current therapeutics for obstetric APS have on HEEC function. Herein, we report that aPL modulates HEEC angiogenic factor and chemokine production, in part through TLR4 activation, and disrupts angiogenesis. Furthermore, LMWH and ASA, in general, exacerbate rather than protect against these aPLmediated changes in HEEC function.
Previous studies found that aPL inhibits HEEC VEGF secretion; STAT3 phosphorylation; NFκB activity; and their ability to form vessel tube-like structures in vitro. [24] [25] [26] However, little else is known about their responses to aPL or the mechanisms involved. What these studies did highlight was a role for domain V of β 2 GPI as the peptide TIFI, that shares homology with the aPL-binding site of domain V, blocked these responses. 26 In our current study, using an aPL that binds to domain V of β 2 GPI, 40 we found that HEEC pro-angiogenic (VEGF, PlGF) and anti-angiogenic factor production (sFlt-1) was augmented, while basal chemokine secretion (MCP-1, G-CSF, GRO-α) was inhibited. In addition, HEEC angiogenesis was inhibited.
While anti-angiogenic sFlt-1 is associated with promoting hypertension and proteinuria in preeclampsia, 45 there is also evidence that sFlt-1 contributes to poor placentation by impairing endothelial function, impacting uterine vessel remodeling, 46, 47 and blocking the action of VEGF and PlGF, which promote trophoblast differentiation and invasion, 48 and angiogenesis. [49] [50] [51] Thus, although HEEC production of pro-angiogenic VEGF and PIGF was also increased, the elevated sFlt-1 response may contribute to the impaired HEEC angiogenesis that we, and others, [24] [25] [26] have observed. Moreover, the aPL-induced upregulation of HEEC VEGF production may drive the sFlt-1 response. 51 The differences in our studies demonstrating elevated HEEC VEGF secretion in response to aPL, while Di Simone's group showed a reduction in this pro-angiogenic factor, may be explained by differences in culture conditions or in the use of our monoclonal domain V aPL compared to their use of polyclonal aPL. 24, 25 In this study, we also found that aPL suppressed HEEC secretion of chemokines that promote trophoblast invasion (G-CSF), 52 and recruit macrophages and natural killer cells (MCP-1, GRO-α) that are necessary for normal spiral artery remodeling. [53] [54] [55] [56] These data suggest that aPL may contribute to the shallow trophoblast invasion and disrupted spiral artery transformation seen in obstetric APS 6 by directly impacting the uterine endothelium, in addition to targeting the placental trophoblast. remodeling. 59 Our studies also highlight that being of fetal origin, and generating a distinct angiogenic and chemokine profile in response to aPL, HUVECs may not be the best model for studying the endothelium in either systemic or obstetric APS.
A role for TLR4 has been demonstrated in aPL-mediated thrombosis 60,61 and in aPL-mediated trophoblast inflammation. 22 In studies using HUVECs, β 2 GPI interacts directly with TLR4 and mediates aPLinduced endothelial cell activation. [28] [29] [30] 62 HEECs express functional TLRs, including TLR4. 36 In this current study, TLR4 was found to mediate the aPL-induced suppression of HEEC MCP-1 secretion, but was not involved in any of the other responses tested, suggesting a role for additional cell surface receptors that aPL may recruit. These could include TLR2 63 or ApoER 2.
64
LMWH is commonly used as an anticoagulant treatment in systemic APS, and early initiation of aspirin (prior to 16 weeks of gestation) is thought to be beneficial for fetal development. 65 Both therapies are given empirically to women with recurrent miscarriage, whether it is due to APS or not. 13, 66, 67 In women with aPL, while LMWH, either alone or in combination with aspirin, has been shown to decrease rates of fetal loss, results are conflicting. 
